AtheroGenics endocrine, cardiovascular news

AtheroGenics said it does not expect to have any remaining funds to distribute to shareholders after the sale of the company's assets. AtheroGenics and its financial advisor, Merriman Curhan Ford & Co. has received initial offers from potential purchasers, but they do not expect the offers plus the company's current cash will exceed AtheroGenics' debt. At Sept. 30, 2008, AtheroGenics had $52.7 million in cash, a nine-month operating loss of $31.3 million, and $306.7 million in debt. ...